Medocriptine

Bromocriptine, the active ingredient in Medocriptine, is a dopamine agonist presented as an oral tablet for oral use. It treats hyperprolactinemia, Parkinson's disease and is used as an adjunct in type 2 diabetes management.

GNH USA supplies Medocriptine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Medocriptine, a dopamine agonist, acts on dopaminergic pathways to address several endocrine and neurologic conditions. - Hyperprolactinemia: reduces excess prolactin secretion, normalizing menstrual cycles and restoring fertility. - Parkinson's disease: improves motor function and reduces rigidity by stimulating central dopamine receptors. - Type 2 diabetes mellitus (adjunct): enhances glycemic control when added to standard antidiabetic therapy.

Bromocriptine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Headache - Dizziness - Fatigue - Hypotension - Abdominal discomfort

Serious or Rare Side Effects: - Valvular heart disease - Pulmonary fibrosis - Severe hypotension - Psychosis or hallucinations - Seizures - Hepatic dysfunction

When prescribing Medocriptine, clinicians should observe several precautionary measures. - Monitor prolactin levels: assess efficacy in hyperprolactinemia. - Evaluate cardiovascular status: watch for hypotension and valvular issues. - Review psychiatric history: risk of psychosis in susceptible patients. - Adjust for hepatic impairment: use with caution in liver disease. - Adjust for renal impairment: consider dose modification in severe renal dysfunction. - Store at ambient temperature: keep in original packaging, protect from moisture.

Bromocriptine can interact with other medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Ergot derivatives: combined use may cause severe vasospasm. - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Antipsychotics (dopamine antagonists): may diminish bromocriptine efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): increase bromocriptine plasma levels. - Antihypertensive agents: additive hypotensive effect.